Search

Your search keyword '"SÁNCHEZ LORA, J"' showing total 2 results
Start Over Author "SÁNCHEZ LORA, J" Publication Type Academic Journals
2 results on '"SÁNCHEZ LORA, J"'

1. Lessons from the "Euro-Lupus Cohort".

Author

Cervera R, Abarca-Costalago M, Abramovicz D, Allegri F, Annunziata P, Aydintug AO, Bacarelli MR, Bellisai F, Bernardino I, Biernat-Kaluza E, Blockmans D, Boki K, Bracci L, Campanella V, Camps MT, Carcassi C, Cattaneo R, Cauli A, Chwalinska-Sadowska H, Contu L, Cosyns JP, Danieli MG, D'Cruz D, Depresseux G, Direskeneli H, Domènech I, Espinosa G, Fernández-Nebro A, Ferrara GB, Font J, Frutos MA, Galeazzi M, García-Carrasco M, García-Iglesias MF, García-Tobaruela A, George J, Gil A, González-Santos P, Grana M, Gül A, Haga HJ, de Haro-Liger M, Houssiau F, Hughes GR, Ingelmo M, Jedryka-Góral A, Khamashta MA, Lavilla P, Levi Y, López-Dupla M, López-Soto A, Maldykowa H, Marcolongo R, Mathieu A, Morozzi G, Nicolopoulou N, Papasteriades C, Passiu G, Perelló I, Petera P, Petrovic R, Piette JC, Pintado V, de Pita O, Popovic R, Pucci G, Puddu P, de Ramón E, Ramos-Casals M, Rodríguez-Andreu J, Ruiz-Irastroza G, Sánchez-Lora J, Sanna G, Scorza R, Sebastini GD, Sherer Y, Shoenfeld Y, Simpatico A, Sinico RA, Smolen J, Tincani A, Tokgöz G, Urbano-Márquez A, Vasconcelos C, Vázquez JJ, Veronesi M, Vianni J, and Vivancos J

Subjects
Adolescent, Adult, Age of Onset, Antibodies, Antinuclear blood, Cohort Studies, Europe epidemiology, Female, Humans, Lupus Erythematosus, Systemic blood, Lupus Erythematosus, Systemic mortality, Male, Middle Aged, Prognosis, Prospective Studies, Survival Rate, Lupus Erythematosus, Systemic epidemiology
Abstract

The "Euro-Lupus Cohort" is composed by 1,000 patients with systemic lupus erythematosus (SLE) that have been followed prospectively since 1991. These patients have been gathered by a European consortium - the "Euro-Lupus Project Group". This consortium was originated as part of the network promoted by the "European Working Party on SLE", a working group created in 1990 in order to promote research in Europe on the different problems related to this disease. The "Euro-Lupus Cohort" provides an updated information on the SLE morbidity and mortality characteristics in the present decade as well as defines several clinical and immunological prognostic factors.

Published
2002

2. [Compliance, efficacy and tolerability of the therapeutic regimen recommended by National Consensus on Tuberculosis].

Author

Colmenero JD, García-Ordoñez MA, Sebastián MD, Pérez-Ruiz E, Sánchez-Lora J, Sánchez-González J, Bentabol G, and Juárez C

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, HIV Infections complications, Humans, Infant, Male, Middle Aged, Patient Compliance, Prospective Studies, Recurrence, Tuberculosis complications, Tuberculosis mortality, Tuberculosis, Multidrug-Resistant complications, Tuberculosis, Multidrug-Resistant drug therapy, Tuberculosis, Multidrug-Resistant epidemiology, Anti-Bacterial Agents, Antitubercular Agents therapeutic use, Drug Therapy, Combination therapeutic use, Isoniazid therapeutic use, Pyrazinamide therapeutic use, Rifampin therapeutic use, Tuberculosis drug therapy
Abstract

Background: To study the degree of adhesion, efficacy, and tolerance of therapeutic guidelines advocated by the National Consensus on tuberculosis., Methods: A prospective study of a cohort of 84 patients receiving a diagnosis of tuberculosis in a Basic General Health Area between 1-3-1993 and 28-2-1994 treated with the regimen recommended by the National Council. The patients were evaluated clinically and microbiologically during the treatment and during twelve months follow-up., Results: Fifty-two patients (61.9%) were male and 32 (38.1%) female, aged 29.9 +/- 19.7 years (r = 1-84 years). Seventy-four (88.1%) were index cases and 10 (11.4%) household contacts. Eight patients (9.5%) were also infected with HIV, 71 (84.5%) presented pulmonary tuberculosis and 13 (15.5%) extrapulmonary forms. Therapeutic compliance was correct in 80 cases (95.2%) and incorrect in 4 (4.8%). It was well-tolerated in 73 patients (91.2%), there was slight toxicity in five (6.3%) and severe in two (2.5%). Seventy-four patients (88.1%) were cured, there was one therapeutic failure (1.2%) and five relapses (6%). Overall mortality was 4.8% and attributable mortality 1.2%., Conclusion: Our results seem to confirm a high degree of adhesion, good tolerance and acceptable therapeutic efficacy of the scheme proposed by the National Council.

Published
1997

Catalog

Books, media, physical & digital resources
See catalog results